In the Press
Fzata selected to be a Mid-Atlantic Innovation Celebration awards finalist!
FZATA RECENT GRANTS
7/22/2021 Fzata WINS NIH PHASE 2 SBIR GRANT
Grant will support development of, "A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection". This will be a diagnostic ELISA to assist physicians in selecting appropriate treatment for patients at risk of C. Diff infection.
5/1/2021 Fzata WINS NIH SBIR FAST TRACK GRANT ON IBD NOVEL IMMUNOTHERAPY
Fzata is awarded a NIH SBIR Fast track grant on our very first IBD project, a novel oral yeast immunotherapies for Ulcerative Colitis.
3/30/2021 Fzata WINS NIH SBIR FAST-TRACK GRANT
Fzata wins NIH SBIR Fast-track grant to support the development of FZ002.
Fzata Announces First-in-Class “Live Biologics In A Pill” Platform Entering Manufacturing Phase
Fzata, Inc. is developing our ground-breaking “Live Biologics In A Pill” platform for oral delivery of live biologics. Live Biologics In A Pill will open up a new route of oral administration for innovative live biologic therapeutics. Fzata is pleased to announce that our lead drug, FZ002, has advanced to manufacturing stage and IND-enabling studies. FZ002 is a first-in-class live biotherapeutic product (LBP) yeast for the treatment of Clostridioides difficile (C. diff) infection. C. diff bacteria can cause life-threatening diarrhea. Infections occur most often in people who have taken antibiotics for other conditions. It is the most common healthcare-associated infection and the CDC has labeled it at the highest urgent threat level. Click for Full Article
FZ002 R&D is published in top journal
Research on Fzata's leading drug candidate, FZ002, was published in
Science Translational Medicine (2020 Oct 28;12(567)).
This break through study was reported by many journals, including Science magazine (https://www.sciencemag.org/news/2020/10/antibody-producing-yeast-vanquishes-deadly-gut-infection-mice), Medical Press (https://medicalxpress.com/news/2020-10-yeast-common-bacterial-intestinal-infection.html), BiotechScope (https://biotechscope.com/antibody-secreting-yeast-immunotherapy-to-treat-deadly-gut-infection/) etc.
Fzata is spotlighted by EAGB
March 1, 2020
EAGB selected Fzata as their Industry Spotlight: Life Science company.
Fzata, Inc. Wins 3rd SBIR Fund
Fzata is awarded an SBIR grant to support the development of a novel companion diagnostic assay for C. diff infection
Fzata Wins 2nd SBIR fund
Fzata receives an SBIR Phase I grant to support the development of a novel immunotherapy against comorbidity of C. diff infection and Inflammatory Bowel Disease
Fzata Wins NIH R01 Grant
March 1, 2017
Fzata is awarded an NIH R01 grant to support the development of a novel multi- specific antibody against C. diff infection.
Fzata is honored "2017 Maryland Incubator Company of the Year: Best Life Science Company"
It's our great honor to be selected as the Maryland best life science incubator company! Saul Ewing, the Maryland Technology Development Corporation (TEDCO) and McGladrey established the Maryland Incubator Company of the Year Awards in 2001.
Fzata, Inc. Wins Its First SBIR Grant
Fzata is awarded a SBIR Phase I grant from NIAID to support the study of a novel oral immuo-therapy against C. diff infection.
As NIH grant awardee, Fzata will strictly follow the NIH policy on Financial Conflict of Interest.
We are excited to announce that Northern Virginia Chamber of Commerce has awarded Fzata as a finalist for its 12th annual Mid-Atlantic Innovation Celebration Award program showcasing the region’s greatest and most creative minds at work! We look forward to joining the celebration on May 12.
May 12, 2022. Fzata is honored that Northern Virginia Chamber of Commerce has selected The Company as the Biotechnology winner for the 12th annual Mid-Atlantic Innovation Celebration Award program showcasing the region’s greatest and most creative minds at work. BioPYM innovation allowing biologics in a pill will be a game changer for those dealing with needle administered biologics!